A citation-based method for searching scientific literature

Meihua Jin, Dong Eun Song, Jonghwa Ahn, Eyun Song, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim. Cancers (Basel) 2021
Times Cited: 6







List of co-cited articles
9 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
421
66


Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R Michael Tuttle,[...]. JAMA 2013
587
50

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
721
50

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
33


BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Rossella Elisei, Clara Ugolini, David Viola, Cristiana Lupi, Agnese Biagini, Riccardo Giannini, Cristina Romei, Paolo Miccoli, Aldo Pinchera, Fulvio Basolo. J Clin Endocrinol Metab 2008
372
33

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
334
33

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
560
33


BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features.
Chenlei Shi, Jia Cao, Tiefeng Shi, Meihua Liang, Chao Ding, Yichen Lv, Weifeng Zhang, Chuanle Li, Wenchao Gao, Gang Wu,[...]. World J Surg Oncol 2020
3
33

Molecular Testing for Indeterminate Thyroid Nodules-When the Rubber Meets the Road.
Jennifer L Marti, Ashok R Shaha. JAMA Otolaryngol Head Neck Surg 2019
4
25

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
168
16


Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile.
Carrie C Lubitz, Konstantinos P Economopoulos, Amanda C Pawlak, Kerry Lynch, Dora Dias-Santagata, William C Faquin, Peter M Sadow. Thyroid 2014
56
16

Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis.
Xiaoyun Liu, Marco Medici, Norra Kwong, Trevor E Angell, Ellen Marqusee, Matthew I Kim, P Reed Larsen, Nancy L Cho, Matthew A Nehs, Daniel T Ruan,[...]. Thyroid 2016
48
16

Does bethesda category predict aggressive features in malignant thyroid nodules?
David A Kleiman, Toni Beninato, Ashwin Soni, Yiyan Shou, Rasa Zarnegar, Thomas J Fahey. Ann Surg Oncol 2013
16
16

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. PLoS Med 2009
16

Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.
Linwah Yip, Marina N Nikiforova, Sally E Carty, John H Yim, Michael T Stang, Mitchell J Tublin, Shane O Lebeau, Steven P Hodak, Jennifer B Ogilvie, Yuri E Nikiforov. Surgery 2009
124
16

The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.
Tanya Chen, Brian M Gilfix, Juan Rivera, Nader Sadeghi, Keith Richardson, Michael P Hier, Véronique-Isabelle Forest, Dina Fishman, Derin Caglar, Marc Pusztaszeri,[...]. Thyroid 2020
17
16

American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making.
Robert L Ferris, Zubair Baloch, Victor Bernet, Amy Chen, Thomas J Fahey, Ian Ganly, Steven P Hodak, Electron Kebebew, Kepal N Patel, Ashok Shaha,[...]. Thyroid 2015
143
16


Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
David L Steward, Sally E Carty, Rebecca S Sippel, Samantha Peiling Yang, Julie A Sosa, Jennifer A Sipos, James J Figge, Susan Mandel, Bryan R Haugen, Kenneth D Burman,[...]. JAMA Oncol 2019
171
16

Molecular testing in diagnosis of indeterminate thyroid cytology: Trends and drivers.
Neeta Kumar, Ruchika Gupta, Sanjay Gupta. Diagn Cytopathol 2020
5
20

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives.
Fabiana Crispo, Tiziana Notarangelo, Michele Pietrafesa, Giacomo Lettini, Giovanni Storto, Alessandro Sgambato, Francesca Maddalena, Matteo Landriscina. Cancers (Basel) 2019
38
16

Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.
Fulvio Basolo, Liborio Torregrossa, Riccardo Giannini, Mario Miccoli, Cristiana Lupi, Elisa Sensi, Piero Berti, Rossella Elisei, Paolo Vitti, Angelo Baggiani,[...]. J Clin Endocrinol Metab 2010
130
16

Preoperative detection of RAS mutation may guide extent of thyroidectomy.
Snehal G Patel, Sally E Carty, Kelly L McCoy, N Paul Ohori, Shane O LeBeau, Raja R Seethala, Marina N Nikiforova, Yuri E Nikiforov, Linwah Yip. Surgery 2017
39
16

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
396
16

The Role of Molecular Testing for the Indeterminate Thyroid FNA.
Esther Diana Rossi, Liron Pantanowitz, William C Faquin. Genes (Basel) 2019
25
16

Does Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP) Have a Unique Molecular Profile?
Tamar C Brandler, Cheng Z Liu, Margaret Cho, Fang Zhou, Joan Cangiarella, Melissa Yee-Chang, Yan Shi, Aylin Simsir, Wei Sun. Am J Clin Pathol 2018
27
16

Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis.
Kristine S Wong, Sara E Higgins, Ellen Marqusee, Matthew A Nehs, Trevor Angell, Justine A Barletta. Endocr Pathol 2019
19
16


Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
Linwah Yip, Marina N Nikiforova, Jenny Y Yoo, Kelly L McCoy, Michael T Stang, Michaele J Armstrong, Kristina J Nicholson, N Paul Ohori, Christopher Coyne, Steven P Hodak,[...]. Ann Surg 2015
69
16

Molecular mutations as a possible factor for determining extent of thyroid surgery.
Joshua R Krasner, Nourah Alyouha, Marc Pusztaszeri, Veronique-Isabelle Forest, Michael P Hier, Galit Avior, Richard J Payne. J Otolaryngol Head Neck Surg 2019
21
16

ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Dimpi Desai, Marcos Lepe, Zubair Wahid Baloch, Susan J Mandel. Cancer Cytopathol 2021
20
16

Molecular approaches to thyroid cancer diagnosis.
Susan J Hsiao, Yuri E Nikiforov. Endocr Relat Cancer 2014
63
16

Concise review: pursuing self-renewal and pluripotency with the stem cell factor Nanog.
Arven Saunders, Francesco Faiola, Jianlong Wang. Stem Cells 2013
72
16


Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively.
Norisato Mitsutake, Atsuhiko Iwao, Kazuhiro Nagai, Hiroyuki Namba, Akira Ohtsuru, Vladimir Saenko, Shunichi Yamashita. Endocrinology 2007
183
16

Cytokine-regulated GADD45G induces differentiation and lineage selection in hematopoietic stem cells.
Frederic B Thalheimer, Susanne Wingert, Pangrazio De Giacomo, Nadine Haetscher, Maike Rehage, Boris Brill, Fabian J Theis, Lothar Hennighausen, Timm Schroeder, Michael A Rieger. Stem Cell Reports 2014
33
16

The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells.
Silvia Peppicelli, Elena Andreucci, Jessica Ruzzolini, Francesca Bianchini, Chiara Nediani, Claudiu T Supuran, Lido Calorini. J Enzyme Inhib Med Chem 2020
17
16

Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH.
Eliska Svastová, Alzbeta Hulíková, Monika Rafajová, Miriam Zat'ovicová, Adriana Gibadulinová, Angela Casini, Alessandro Cecchi, Andrea Scozzafava, Claudiu T Supuran, Jaromír Pastorek,[...]. FEBS Lett 2004
547
16

Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.
Andrés Coca-Pelaz, Jatin P Shah, Juan C Hernandez-Prera, Ronald A Ghossein, Juan P Rodrigo, Dana M Hartl, Kerry D Olsen, Ashok R Shaha, Mark Zafereo, Carlos Suarez,[...]. Adv Ther 2020
35
16

Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
F E Lock, P C McDonald, Y Lou, I Serrano, S C Chafe, C Ostlund, S Aparicio, J-Y Winum, C T Supuran, S Dedhar. Oncogene 2013
233
16

Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.
Nathaniel H Boyd, Kiera Walker, Joshua Fried, James R Hackney, Paul C McDonald, Gloria A Benavides, Raffaella Spina, Alessandra Audia, Sarah E Scott, Catherine J Landis,[...]. JCI Insight 2017
64
16

Cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts.
Delphine Tamara Marie-Egyptienne, Naz Chaudary, Tuula Kalliomäki, David William Hedley, Richard Peter Hill. Oncotarget 2017
6
16

Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma.
Hidehiro Kon-no, Genichiro Ishii, Kanji Nagai, Junji Yoshida, Mitsuyo Nishimura, Michiya Nara, Tomoki Fujii, Yukinori Murata, Hideaki Miyamoto, Atsushi Ochiai. Lung Cancer 2006
43
16

Catalysis and pH control by membrane-associated carbonic anhydrase IX in MDA-MB-231 breast cancer cells.
Ying Li, Chingkuang Tu, Hai Wang, David N Silverman, Susan C Frost. J Biol Chem 2011
40
16

Overexpression of PROM1 (CD133) confers poor prognosis in non-small cell lung cancer.
Zhi-Xin Qiu, Shuang Zhao, Xian-Ming Mo, Wei-Min Li. Int J Clin Exp Pathol 2015
15
16

Glycolysis-related protein expression in thyroid cancer.
Ji Hae Nahm, Hye Min Kim, Ja Seung Koo. Tumour Biol 2017
25
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.